Is Adaptive Biotechnologies Corp (ADPT) undervalued? · rev $179.0M
Adaptive Biotechnologies Corp (ADPT) is a diagnostics & research company listed on NASDAQ.
This page asks whether Adaptive Biotechnologies Corp (ADPT) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ADPT revenue for 2024-12-31 was $179.0M. Net income was -$159.6M. Revenue was up 5.1% from 2023-12-31 to 2024-12-31. ADPT currently screens at market cap $2.69B.
ADPT currently screens at market cap $2.69B. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ADPT 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ADPT to the stock page model before you treat a low multiple as a gift.
Not investment advice.